Voltron

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Completion of a Trial Protocol to Study its Self Assembling Vaccine to Target Prostate Stem Cell Antigen

Retrieved on: 
Monday, November 20, 2023

NEW YORK, Nov. 20, 2023 /PRNewswire/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that it has finalized the protocol for a Dose-Ranging Efficacy Study of VTX-0P4, a protein-based cancer vaccine targeting Prostate Stem Cell Antigen (PSCA).

Key Points: 
  • NEW YORK, Nov. 20, 2023 /PRNewswire/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that it has finalized the protocol for a Dose-Ranging Efficacy Study of VTX-0P4, a protein-based cancer vaccine targeting Prostate Stem Cell Antigen (PSCA).
  • Voltron recently demonstrated immunogenicity against PSCA in a double blind pre-clinical trial conducted at the Vaccine and Immunotherapy Center at the Massachusetts General Hospital.
  • In that trial VTX-0P4 significantly augmented T-Cell responses when compared to controls against this important tumor target while, once again, exhibiting a very clean safety profile.
  • "We are excited to initiate Voltron's PSCA pre-clinical efficacy trial," said James Ahern, Managing Partner of Laidlaw & Company and co-founder of Lucius Partners.

Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vacc

Retrieved on: 
Thursday, October 5, 2023

This research collaboration resulted from a $5.88 million award that VIC received from the U.S. Department of Defense (“DoD”).

Key Points: 
  • This research collaboration resulted from a $5.88 million award that VIC received from the U.S. Department of Defense (“DoD”).
  • The award is intended to be used to advance the development of a Self-Assembling Vaccine (“SAV”) Platform for rapid production of prophylactic vaccines for various infectious diseases.
  • SAVs have demonstrated the potential to cause more efficacious immune response and protection, which provides a promising strategy for vaccine construction.
  • We anticipate that this work will help create a valuable infectious disease pipeline as well as contribute to our Immuno-Oncology programs.”

DataStax Closes Strong Fiscal Year Capped with a New Mandate

Retrieved on: 
Tuesday, February 28, 2023

“It was another banner year for DataStax, topped with a clear, new company mandate: make it possible for anyone with real-time data to do real-time AI,” said Chet Kapoor, DataStax chairman and CEO.

Key Points: 
  • “It was another banner year for DataStax, topped with a clear, new company mandate: make it possible for anyone with real-time data to do real-time AI,” said Chet Kapoor, DataStax chairman and CEO.
  • “We’re supporting a vibrant and growing group of organizations who depend on DataStax to manage massive amounts of data in real time.
  • In addition, product and technology advancements from the company helped drive new customer acquisition, leading to a 40% growth in new DataStax logos year-over-year.
  • “We use DataStax to help us quickly fetch and store critical historical data to aid in the fraud analysis of each order.

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Industry Veteran Dr. Tony Hodges has Joined the Company as Senior Scientific Advisor

Retrieved on: 
Tuesday, July 12, 2022

NEW YORK, July 12, 2022 /PRNewswire/ -- Voltron Therapeutics, Inc. today announced that life science veteran, Dr. Tony Hodges, has joined the Company as Senior Scientific Advisor.

Key Points: 
  • NEW YORK, July 12, 2022 /PRNewswire/ -- Voltron Therapeutics, Inc.today announced that life science veteran, Dr.Tony Hodges, has joined the Company as Senior Scientific Advisor.
  • Dr. Tony N. Hodges is currently Chief Medical Officer, La Jolla Pharmaceutical .
  • Previous experience included roles at the University of Southern California Keck School of Medicine in Los Angeles.
  • The significant progress made to date in this area of customizable cellular immunity combined with a scientifically robust platform is impressive.

Voltron Therapeutics, Inc.’s Scientific Co-Founder Dr. Mark C. Poznansky has Guest Essay Published in the New York Times

Retrieved on: 
Tuesday, July 20, 2021

NEW YORK, July 20, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that a the Companys Scientific Co-Founder, Dr. Mark C. Poznanskys guest essay titled The Vaccines We Have Are Good.

Key Points: 
  • NEW YORK, July 20, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that a the Companys Scientific Co-Founder, Dr. Mark C. Poznanskys guest essay titled The Vaccines We Have Are Good.
  • But They Could Be So Much Better , was published in the New York Times on June 10, 2021.
  • Dr. Poznansky also serves as a scientific founder for Voltron Therapeutics, helping to advise on the early clinical research and implementation of testing in the clinical setting among other things.
  • As a Scientific Co-Founder of Voltron Therapeutics, Dr. Poznansky has been instrumental in the development of HaloVax, a Self-Assembling Vaccine (SAV) against COVID-19.

VOLTRON TRAVEL TO PARTNER WITH THURGOOD MARSHALL COLLEGE FUND

Retrieved on: 
Thursday, June 24, 2021

Gibson, currently starring in F9: The Fast Saga says, Partnering with the Thurgood Marshall College Fund is a true privilege.

Key Points: 
  • Gibson, currently starring in F9: The Fast Saga says, Partnering with the Thurgood Marshall College Fund is a true privilege.
  • We applaud Tyrese Gibson and Voltron Travel for their commitment to the Black College Community, TMCF Vice President of Development Betsy Burton-Strunk said.
  • Gibson recently relaunched Voltron Travel, an online travel platform powered by Priceline Partner Network.
  • www.VoltronTravel.com
    Established in 1987, the Thurgood Marshall College Fund (TMCF) is the nations largest organization exclusively representing the Black College Community.

BAGAAAAAAAAAAAAAWK! It's National Dance Like a Chicken Day!

Retrieved on: 
Friday, May 14, 2021

Well, it\'s time to stand up and stretch your wings with the characters from Disney Junior\'s animated series "The Chicken Squad," premiering tonight at 7:30 p.m. EDT/PDT on Disney Junior and DisneyNOW.\nThis press release features multimedia.

Key Points: 
  • Well, it\'s time to stand up and stretch your wings with the characters from Disney Junior\'s animated series "The Chicken Squad," premiering tonight at 7:30 p.m. EDT/PDT on Disney Junior and DisneyNOW.\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210514005420/en/\n"The Chicken Squad" dance is featured in every episode with the "Chicken Charge" anthem that the chickens sing upon determination of a new mission.\nWe\'re not yoking around!
  • GRAMMY\xc2\xae Award winner Alex Geringas ("Voltron: Legendary Defender") and EmmyAward-nominated Mike Himelstein ("Mickey Mouse Clubhouse") are the series\' songwriters.
  • Images are not to be archived, altered, duplicated, resold, retransmitted or used for any other purposes without written permission of Disney Channels Worldwide.

Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19

Retrieved on: 
Wednesday, March 24, 2021

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced positive data from its second set of preclinical animal testing of its HaloVax Self-Assembling Vaccine (SAV) against COVID-19.

Key Points: 
  • NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced positive data from its second set of preclinical animal testing of its HaloVax Self-Assembling Vaccine (SAV) against COVID-19.
  • This enables rapid iteration and up-to-date data informed changes in the peptide sequences to enable swift production and accommodate potential changes in the pathogen itself.
  • Results demonstrated that the self-assembling vaccine construct did indeed significantly increase both helper and cytotoxic T cell responses to the vaccine targeted antigens compared to controls.
  • The vaccine is currently in development by HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc.

Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman

Retrieved on: 
Thursday, January 28, 2021

Mr. Zook also serves on the Laidlaw Venture Partners (LVP), the venture capital arm ofLaidlaw & Company (UK) Ltd., Investment and Operations Committee.

Key Points: 
  • Mr. Zook also serves on the Laidlaw Venture Partners (LVP), the venture capital arm ofLaidlaw & Company (UK) Ltd., Investment and Operations Committee.
  • Mr. Zook brings to Voltron a wealth of commercialization experience in the life science industry, gained primarily through his career at AstraZeneca Plc.
  • Under Mr. Zooks leadership, AstraZeneca commercialized ten blockbuster brands, each over $1 billion in sales.
  • I am delighted to have Tony assume the newly formed role of Executive Chairman of Voltrons Board of Directors.

Voltron Therapeutics, Inc. Executes Manufacturing Agreement with Global Pharmaceutical Contract Development and Manufacturing Organization

Retrieved on: 
Wednesday, September 16, 2020

NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it has executed a manufacturing agreement for its vaccine portfolio with a global pharmaceutical contract development and manufacturing organization.

Key Points: 
  • NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it has executed a manufacturing agreement for its vaccine portfolio with a global pharmaceutical contract development and manufacturing organization.
  • The agreement partners Voltron with a multi-national company known for enabling companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients.
  • This enables rapid iteration and up-to-date data informed changes in the peptide sequences to enable swift production of the vaccine.
  • We are pleased to have executed a manufacturing agreement with an international contract manufacturer for our vaccine portfolio.